Weekly administration of paclitaxel: Theoretical and clinical basis

Critical Reviews in Oncology/Hematology

Volumn 44, Issue SUPPL., 2002, Pages 3-13

  Marchetti, Paolo ^a   Urien, Saïk ^b   Cappellini, Giancarlo Antonini ^a   Ronzino, Graziana ^a   Ficorella, Corrado ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

Clinical efficacy; Dose density; p53; Premedication; Rationale; Weekly paclitaxel

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DNA; FLUOROURACIL; IRINOTECAN; PACLITAXEL; PROTEIN P53; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CELL POPULATION; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; DOSE CALCULATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MICROTUBULE; MITOSIS; OVARY CARCINOMA; PREMEDICATION; REVIEW; TOXICITY; TUMOR GROWTH;

EID: 12244278990     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1040-8428(02)00109-9     Document Type: Review

References (92)

1. Skipper H.E., Schabel F.M., Wilcox W.S. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother. Rep. 35:1964;1-11.
2. Seidman A.D., Hudis C.A., Albanel J., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16:1998;3353-3361.
3. Breier S., Lebedinsky C., Ayaviri C., et al. Long-term weekly Taxol® (paclitaxel) injection over 1-hour infusion: a phase II trial report. Breast Cancer Res. Treat. 57:1999;124. abstract 523.
4. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 24:(Suppl 10):1997;S10.3-S10.10.
5. Belotti D., Vergani V., Drudis T., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1996;1843-1849.
6. Milross C.G., Mason K.A., Hunter N.R., et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst. 88:1996;1308-1314.
7. Rowinsky E.K., Donehower R.C. Paclitaxel. New Engl. J. Med. 332:1995;1004-1014.
8. Dustin P. Microtubules. Sci. Am. 243:1980;66-76.
9. Nogales E., Wolf S.G., Khan I.A., Luduena R.F., Downing K.H. Structure of tubuline at 6.5A and location of the Taxol-binding site. Nature. 375:1995;424-427.
10. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem. Pharmacol. 400:1999;464-468.
11. Wang T.H., Wang H.S., Soong Y.K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 88:2000;2619-2628.
12. Blagosklonny M.V., Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int. J. Cancer. 83:1999;151-156.
13. King T.C., Akerley W., Fan A.C., et al. p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung cancer. Cancer. 89:2000;769-773.
14. Takahashi M., Kigawa J., Minagawa Y., et al. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur. J. Cancer. 36:2000;1863-1868.
15. Blagosklonny M.V., Bishop P.C., Robey R., Fojo T., Bates S.E. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. Cancer Res. 60:2000;3425-3428.
16. Zhang C.C., Yang J.M., Bash-Babula J., et al. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule -associated protein 4. Cancer Res. 59:1999;3663-3670.
17. Lavarino C., Pilotti S., Oggionni M., et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J. Clin. Oncol. 18:2000;3936-3945.
18. De Feudis P., Vignati S., Rossi C., et al. Driving p53 response to Bax activation greatly enhances sensitivity to Taxol by inducing massive apoptosis. Neoplasia. 2:2000;202-207.
19. Gottesman M.M., Hrycyna C.A., Schoenlein P.V., et al. Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 29:1995;607-649.
20. Cabral F., Trimble E., Reed E., Sarosy G. Future directions with taxane therapy. Hematol. Oncol. Clin. N. Am. 13:1999;21-41.
21. Kavallaris M., Ku D.Y.S., Burkhart C., et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta tubulin isotypes. J. Clin. Invest. 100:1997;1282-1293.
22. Kuo D.Y.S., Mallick S., Shen H.J., et al. Analysis of MDR1 expression in normal and malignant endometrium by reverse transcription-polymerase chain reaction and immunohistochemistry. Clin. Cancer Res. 2:1996;1981-1992.
23. Giannakakou P., Sackett D.L., Kang Y.K., et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272:1997;17118-17125.
24. Olmsted J.B., Borisy G.G. Characterization of microtubule assembly in porcine brain extracts by viscometry. Biochemisry. 12:1993;4282-4289.
25. Wang X.M., Peloquin J.G., Zhai Y., Bulinski J.C., Borisy G.G. Removal of MAP4 from microtubules in vivo produces no discernible phenotype at the cellular level. J. Cell Biol. 132:1996;349-358.
26. Sullivan K.F. Structure and utilization of tubulin isotypes. Ann. Rev. Cell Biol. 4:1988;687-716.
27. Panvichian R., Orth K., Day M.L., Day K.C., Pilat M.J., Pienta K.J. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res. 58:1998;4667-4672.
28. Levasseur L.M., Slocum H.K., Rustum Y.M., Greco W.R. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res. 58:1998;5749-5761.
29. Klauber N., Parangi S., Hamel E., Flynn E., D'Amato R.J. Inhibition of angiogenesis in vivo by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res. 57:1997;81-86.
30. ®): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm. 14:1999;31-36.
31. Moos P.J., Fitzpatrick F.A. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. Natl. Acad. Sci. USA. 95:1998;3896-3901.
32. Markman M., Hall J.B., Spitz D.L., Weiner S., Carson L., Van Le L., Baker M.E. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol. 20:2002;2365-2369.
33. Abu-Rustum N.R., Aghajanian C., Barakat R.R., Fennelly D., Shapiro F., Spriggs D. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin. Oncol. 24:(Suppl 15):1997;62-67.
34. Löffler T.M., Freund W., Lipke J., Hausamen T.U. Schedule and dose intensified paclitaxel (T) as weekly one-hour infusion. Evidence for an improved toxicity profile and response activity in pretreated solid tumors. Semin. Oncol. 23:(6 Suppl 16):1996;32-34.
35. ®): mécanismes d'action et optimization thérapeutique par administration hebdomadaire. La Lettre Pharmacol. 15:2001;15-21.
36. Mross K., Holländer N., Havns B., Schumacher M., Marier-Lang H. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother. Pharmacol. 45:2000;463-470.
37. Gianni L., Keens C.M., Gianni A., et al. Non-linear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13:1995;180-190.
38. Kuh H.J., Jang S.H., Wientjes, Au J.L.S. Computational model of intracellular pharmacokinetics of paclitaxel. J. Pharmacol. Exp. Ther. 293:2000;761-770.
39. Fennelly D., Aghajanian C., Shapiro F., et al. Phase 1 and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15:1997;187-192.
40. Choy H., Akerley W., Safran H., et al. Preliminary analysis of paclitaxel, carboplatin and concurrent radiation in the treatment of patients with advanced non-small cell lung cancer. Semin. Rad. Oncol. 7:(Suppl 1):1997;15-18.
41. Conley B., Jacobs M., Suntharalingam M., et al. The role of paclitaxel/carboplatin and concurrent radiotherapy in unresectable squamous cell carcinoma of the head and neck: recent findings. Semin. Rad. Oncol. 7:(Suppl 1):1997;39-41.
42. Klaasen U., Wilke H., Strumberg D., et al. Phase I study with a weekly 1 hour infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur. J. Cancer. 32A:1996;547-549.
43. Sola S., Lluch A., Garçia-Conde J., et al. Phase II study of weekly paclitaxel in recurrent breast cancer after high-dose chemotherapy. Proc. Am. Soc. Clin. Oncol. 17:1998;. abstract 669.
44. Alvarez A., Mickiewicz E., Pris N., et al. Weekly Taxol high dose intensity (DI) treatment, phase II study. Proc. Am. Soc. Clin. Oncol. 15:1996;183. abstract 383.
45. Luck H.J., Marhenke D., Petry K.U., et al. Weekly paclitaxel monotherapy as salvage treatment in pretreated patients with metastatic breast cancer. Experience with a one-hour schedule. Breast Cancer Res. Treat. 46:1997;58. abstract 233.
46. Breier S., Lebedinsky C., Ayiviri C., et al. Long-term weekly paclitaxel (P) in metastatic breast cancer (MBC). A phase II trial in pretreated patients (pts). Proc. Am. Soc. Clin. Oncol. 17:1998;192. abstract 740.
47. Quock J., Dea G., Lim N., et al. Premedication strategy for weekly paclitaxel based on experience with 1608 infusions of 3- and 4-week paclitaxel. Proc. Am. Soc. Clin. Oncol. 18:1999;165a. abstract 635.
48. Briasoulis E., Karavasilis V., Tzamakou E., Haidou C., Piperidou C., Pavlidis N. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. Anticancer Drugs. 13:2002;481-489.
49. Perez E.A., Vogel C.L., Irwin D.H., Kirshner J.J., Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. 19:2001;4216-4223.
50. Asbury R., Chang A., Boros L., Asbury L., Rubins J. Weekly moderate-dose paclitaxel in advanced breast cancer. Semin. Oncol. 26:(Suppl 18):1999;7.
51. Perez E.A., Vogel C.L., Irwin D.H., Kirshner J.J., Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. 19:2001;4216-4223.
52. Thirapakawong C., Senapad S., Padangsutt P., et al. Phase II study of weekly paclitaxel (Taxol) as a second line chemotherapy in refractory epithelial ovarian cancer (EOC): a multicenter study. Proc. Am. Soc. Clin. Oncol. 20:2001;. abstract 2506.
53. Abu-Rustum N.R., Aghajanian C., Barakat R.R., Fennelly D., Shapiro F., Spriggs D. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin. Oncol. 24:(Suppl 15):1997;S15-62-S15-67.
54. Belani C.P. Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin. Oncol. 28:(Suppl 14):2001;14-16.
55. Chang A.Y., Rubins J., Asbury R., Boros L., Fong Hui L. Weekly paclitaxel in advanced non-small cell lung cancer. Semin. Oncol. 28:(Suppl 14):2001;10-13.
56. Chang A.Y. Weekly paclitaxel and beyond for advanced non-small cell lung cancer. Lung Cancer. 29:(Suppl 2):2000;135.
57. Socinski M.A., Kies M., Unger P., et al. Second-line weekly paclitaxel in patients with advanced non-small cell lung cancer failing first-line carboplatin/paclitaxel. Lung Cancer. 29:(Suppl 1):2000;6.
58. Waintraub S.E., Cantwell S., DeVries J. Phase II study to evaluate the efficacy of weekly paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline +/- taxane +/- PSCT therapy. Proc. Am. Soc. Clin. Oncol. 19:2000;A470.
59. Sikov W., Akerley W., Strenger R., et al. Weekly high-dose paclitaxel in locally advanced and metastatic breast cancer: a BrUOG study. Semin. Oncol. 26:(Suppl 18):1999;6.
60. Waintraub S.E., Cantwell S., DeVries J. Phase II study to evaluate the efficacy of weekly paclitaxel (P) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline (A) +/- taxane (T) therapy. Proc. Am. Soc. Clin. Oncol. 18:1999;A530.
61. Mickiewicz E., Alvarez A.M., Brosio C., et al. A promising second-line treatment with weekly Taxol (T) in anthracycline recurrent, advanced breast cancer (ABC) patients (pts). Proc. Am. Soc. Clin. Oncol. 18:1999;. abstract 515.
62. Lluch A, Tormo G, Martinez de Duenas E, Azagra P, Prosper F, Garcia-Conde J. Activity of weekly paclitaxel in breast cancer recurrences after high dose chemotherapy (HDC) with stem cell support. Ninth Int Congress on Anti-cancer Treatment, Paris, 1999:abstract 0136.
63. Alvarez A.M., Mickiewicz E., Brosio C., et al. Reinduction with weekly Taxol (T) in advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;. abstract 636.
64. Marhenke D, Luck H-J, Scholz U, et al. Weekly paclitaxel for metastatic breast cancer (MBC). Eighth International Congress on Anti-cancer Treatment 1998; abstract 016.
65. 2 in pretreated breast (BC) and ovarian cancer (OC). Proc. Am. Soc. Clin. Oncol. 16:1997;A568.
66. Sikov W., Akerley A., Cummings F., et al. Weekly high-dose paclitaxel in locally advanced (LABC) and metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 16:1997;191a. abstract 669.
67. Chang AY, Boros L, Asbury R, Hui L, Rubins J. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin Oncol 1997;24 (Suppl 17):S17-69-71.
68. Luftner D., Mergenthaler H.G., Grunewald R., Flath B., Budach V., Possinger K. Paclitaxel in a weekly fractionated schedule advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 15:1996;A266.
69. Seidman A.D., Murphy B., Hudis C., et al. Activity of Taxol by weekly 1 hour infusion in patients (pts) with metastatic breast cancer (MBC): a phase II and pharmacologic study. Proc. Am. Soc. Clin. Oncol. 16:1997;A517.
70. Kaern J., Trope C.G., Baekelandt M., Kristensen G.B. Phase II trial of weekly single agent paclitaxel (P) in platinum (PLAT) and paclitaxel refractory ovarian cancer (OC). Proc. Am. Soc. Clin. Oncol. 20:2001;. abstract 810.
71. Alvarez A.M., Mickiewicz E., Rodger J., et al. Weekly Taxol (WT), 3 on 1 off, second-line treatment in ovarian cancer (OC). Proc. Am. Soc. Clin. Oncol. 19:2000;. abstract 1596.
72. Andersson H., Boman M., Ridderheim M., et al. An updated analysis of a randomized study of single-agent paclitaxel (P) given weekly vs. every 3 weeks to patients (pts) with ovarian cancer (OV) treated with prior platinum therapy. Proc. Am. Soc. Clin. Oncol. 19:2000;. abstract 379P.
73. Benedetti-Panici P. Intraperitoneal paclitaxel (IP) in ovarian cancer (OC) patients with small or microscopic residual disease (MRD). Proc. Am. Soc. Clin. Oncol. 19:2000;. abstract 1525.
74. ® in patients with recurrent platinum resistant ovarian cancer. Ann. Oncol. 11:(Suppl 4):2000;85. abstract 379P.
75. 2 in pretreated patients (pts) with breast (BC) and ovarian cancer (OC). Proc. Am. Soc. Clin. Oncol. 16:1997;A568.
76. Akerley W. Paclitaxel in advanced non-small cell lung cancer: an alternative high-dose weekly schedule. Chest. 117:(Suppl 1):2000;152S-155S.
77. Akerley W., Herndon J., Egorin M., et al. CALGB 9731: phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;A1783.
78. Akerley W., Glantz M., Choy H. Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Semin. Oncol. 23:(Suppl 12):1996;14-18.
79. Alberola V., Vidal O., Ordoño F., et al. Low-dose weekly paclitaxel (WP) in the treatment of unresectable or metastatic non-small cell lung cancer (NSCLC). Neurological and electrophysiological evaluation of neurotoxicity. Proc. Am. Soc. Clin. Oncol. 20:2001;. abstract 2837.
80. Fidias P., Supko J.G., Martins R., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin. Cancer Res. 7:2001;3942-3949.
81. Koumakis G., Demeri M., Barbounis V., et al. Is weekly paclitaxel superior to paclitaxel given every three weeks? Results of a phase II trial. Lung Cancer. 35:2002;315-317.
82. Maher J.F., Villalona-Calero M.A. Taxanes and capecitabine in combination: rationale and clinical results. Clin. Breast Cancer. 2:2002;287-293.
83. Nadella P., Shapiro C., Otterson G.A., et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J. Clin. Oncol. 20:2002;2616-2623.
84. Scholz U., Lück H.J., Canzler U., Robner D., Kühnle H. A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer. Oncology (Huntingt). 14:(Suppl 9):2000;44-46.
85. Murren J.R., Blum K., Gallipoli M., McKeon A., Rich R. Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule. Oncol. (Huntingt). 15:(Suppl 1):2001;25-30.
86. Murren J.R., Peccerillo K., DiStasio S.A., et al. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemother. Pharmacol. 46:2000;43-50.
87. Seidman A.D., Fornier M.N., Esteva F.J., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with the analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 19:2001;2587-2595.
88. Diéras V., Beuzeboc P., Laurence V., Piega J.Y., Pouillart P. Interaction between Herceptin and taxanes. Oncology. 61:(Suppl 2):2001;43-49.
89. Xu G., Pan J., Martin C., Yeung S.C.J. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J. Clin. Endocrinol. Met. 86:2001;1769-1779.
90. Hoffmann W., Belka C., Schmidberger H., et al. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer - results from a phase I trial. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;691-696.
91. Chougule P., Wanebo H., Akerley W., et al. Concurrent paclitaxel, carboplatin, and radiotherapy in head and neck cancer. A phase II study-preliminary results. Semin. Oncol. 24:1997;57-61.
92. Konishi K., Tani Y., Minami S., et al. Pharmacokinetic comparison between weekly paclitaxel treatment and by 3 weeks treatment in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;. abstract 2000.